Drug Profile
Research programme: phosphatidylinositol 3-kinase inhibitors - GlaxoSmithKline
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Pyrimidines; Sulfonamides
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA
- 10 Sep 2009 Preclinical trials in Cancer in USA (unspecified route)